Comparative Effectiveness of Tofacitinib and Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis in Real-world Practice: A Prospective Observational Study
doi: 10.1093/rheumatology/keae109 Epub ahead of print
This study by Cho, et al. did not find any significant differences in remission rates in South Korean patients with RA that were treated with tofacitinib versus TNFi in a real-world setting. Remission rates were significantly higher for patients naïve to both JAKi and bDMARDs treated with tofacitinib versus TNFi.
In this observational study, 200 patients were treated with tofacitinib and 455 were treated with TNFi in March 2017–March 2021. Multivariable logistic regression analysis was used to estimate the odds ratio for achieving remission with tofacitinib compared to TNFi, adjusting for potential confounders.
Keywords:
